Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4-Associated Cholangitis

Mark Topazian, Thomas E. Witzig, Thomas C. Smyrk, Jose S. Pulido, Michael J. Levy, Patrick S. Kamath, Suresh T. Chari

Research output: Contribution to journalArticlepeer-review

139 Scopus citations


Background & Aims: Biliary strictures occur in a third of patients with autoimmune pancreatitis and have been termed immunoglobulin G subclass 4 (IgG4) associated cholangitis (IAC). IAC often responds to steroid therapy. Methods: A patient with autoimmune pancreatitis and (IAC) refractory to steroids and 6-mercaptopurine was treated with rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes. Results: The patient's biliary strictures improved after rituximab therapy, permitting removal of his biliary stents. Systemic manifestations of IgG4-associated disease also improved. Conclusions: Rituximab may be a treatment option for patients with refractory or recurrent autoimmune pancreatitis or IAC.

Original languageEnglish (US)
Pages (from-to)364-366
Number of pages3
JournalClinical Gastroenterology and Hepatology
Issue number3
StatePublished - Mar 2008

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4-Associated Cholangitis'. Together they form a unique fingerprint.

Cite this